Go to the top

Life Sciences
Jeong Beom Kim

Associate Professor / UNIST

INTRO

Welcome to the Molecular Biomedicine Laboratory.
By 박수용 2020-06-11

The paradigm of regenerative medicine was thoroughly changed when induced pluripotent stem cells (iPSCs) were first derived by Shinya Yamanaka. Importantly, iPS can be used as a source for patient-specific cell therapies. In addition, the ethical concerns and the limitations associated with embryonic stem cells (ESCs), namely immune rejection, could also be overcome.
Direct conversion is another innovative technique. Because it doesn’t need iPS intermediate state to make patients specific stem cells, it can rule out the possibility of tumorigenecity .

Our research is based on an understanding of the mechanism of iPS reprogramming, direct conversion and the generation of patient-specific stem cells for future cell therapy. The aim is to develop innovative cell therapeutic methods for clinical applications and possible solutions for degenerative and currently incurable disease. In addition, iPS cells and direct conversion can also be used for innovative techniques of drug screening and toxicity tests. Therefore, the therapeutic potential of iPS cell and direct converted cells are very promising.
figure 2
Moreover, we are collaborating with the Max Planck Institute for Molecular Biomedicine (MPI-MBM) located in Muenster, Germany. This collaboration will create synergic effects that will be mutually beneficial. Continuously seeking new areas of collaboration, we will reach out to become a world-class stem cell research group.

People

Professor

JBKim
김정범(Jeong Beom Kim)

– School : School of Life Sciences, UNIST
– Title : Associate Professor
– Address :44919 100 Banyeon-ri, Eonyang-eup, Ulju-gun, Ulsan
– Phone : 052)217-5201
– Fax : 052)217-5269
– E-mail : jbkim@unist.ac.kr

Research Interest
Reprogramming mechanisms of iPS cells
Derivation of adult stem cells from human iPS;
Patient-specific iPS cell generation;
Direct reprogramming of patient-derived somatic cells;
Preclinical applications of iPS cells.

Education and Training

2009 Ph.D. Biology, Muenster University, Max Planck Institute for Molecular Biomedicine,Department of Cell and Developmental Biology, Germany;
2004 M.S. Medical Science (Cancer Biology), onsei University College of Medicine;
2001 B.S. Biology, Dongguk University.

Work Experience

2017-Present  CEO, SuPine Therapeutics Co., Ltd.

2012-2016      Group leader, Max Plank Partner Group-MBL

2010-Present  Director, Hans Schöler Stem Cell Research Center

2010-Present  Associate Professor, UNIST

Awards and Patents

2019 Global Biotech Startup Net-workshop, Top 3 Attractive Startup

2018 Award of HYUNDAI Heavy Industries

2017 Award of the Minister of Small and Medium Business Administration

2017 Young- Korean Academy of Science and Technology (Y-KAST), KAST

2013 Hanrim Leading Scientist Award, KAST

2011 “The leaders of Korea after 10 years”, Dong-A News paper (National)

2010 “The leaders of Korea after 10 years”, Dong-A News paper (National)

2010 Otto-Hahn Award (Max Planck Society, Germany)

2009 MTZ®-MPI-Award (MTZ foundation, Germany)

2008 ISSCR (International Society of Stem Cell Research), Junior Investigator Award, USA

 

Lab Members

>> Doctoral course

Myung Rae Park (박명래)
2
Education
M.S.,KonKuk University, 2008 to 2010
B.S.,Keimyung University, 2001 to 2007

Motto
“‘Trial & error’ is a ladder that reaching for the truth.”

Research Interest
Direct reprogramming; Drug screening.

* contact : rae3208@unist.ac.kr

 

>> Combined MS-doctoral course

Hyun Ah Lee (이현아)
3
Education
B.S., University of Ulsan, 2007 to 2011.

Motto
“Wheresover you go, go with all your heart.”

Research Interest
iPS cells; Direct reprogramming.

* contact : hyuna1000je@nate.com

Soo Yong Park (박수용)
4
Education
B.S., Kyungpook National University, 2005 to 2012

Motto
“Do my best in everything.”

Research Interest
Direct reprogramming, patient-specific stem cell

* contact : shorypark@naver.com

 

Donggyu Nam(남동규)
7
Education
Honours in B.S., University of Toronto, St. George campus, 2006 to 2014

Motto
Just do it.

Research interest
Gene editing, Direct reprogramming/iPS cells

* contact : mymy301@gmail.com

 

>> Master course

Joo Yeong Kang (강주영)

강주영

Education

M.S., Ulsan National Institute of Science and Technology 2019-

B.S., Sungkyunkwan University, 2013-2019

Motto

Live life without regrets.

Research interest

Patient-derived stem cell therapy

*  contact : kangj0594@gmail.com

 

>> Alumni

Hong dae Seo(서홍대)

Education

M.S., Ulsan National Institute of Science and Technology 2016-2019

B.S., Ulsan National Institute of Science and Technology, 2010 -2016

 

Ji Hoon Son(손지훈)

Education

M.S., Ulsan National Institute of Science and Technology 2016-2019

B.S., Ulsan National Institute of Science and Technology, 2012 -2016

 

Yujin Jeong(정유진)
Education
M.S., Ulsan National Institute of Science and Technology 2015-2017
B.S., Incheon national university , 2011 ~ 2014

 

WONG Man Sze(Mancy)
Education
M.S., Ulsan National Institute of Science and Technology 2012-2015
B.S., The Hong Kong University of Science and Technology 2009-2012

 

대학원생, 연구원 모집
By 2020-06-11 대학원생, 연구원 모집–

2010년 8월 UNIST내 Hans Schoeler Stem Cell Research Center(HSSCRC) 출범을 기점으로 저희 연구실에서 2020년 대학원생 및 연구원을 모집합니다.

주된 연구분야는,
1. Human, mouse embryonic stem cell의 pluripotency에 관한 연구
2. iPS technology를 이용하여 somatic 또는 adult stem cell로의 분화 후 animal model에서 검증 하는 preclinical application
3. Non-iPS성 직접교차분화에 관한 연구

현재 세계 최고의 연구기관중 하나인 독일 막스플랑크연구소와 공동연구를 체결하여, 주기적인 공동세미나 개최 및 기술교류를 하고 있으며, 역분화줄기세포제작 및 다른정상 세포로의 분화와 관련된 최고의 기술력을 보유하고 있습니다.

더불어 2010년 6월 말부터 교육과학기술부 주관 미래기반기술개발사업(줄기세포선도연구팀육성사업)에 선정된것을 시작으로, 여러가지 큰 규모의 줄기세포관련 국가과제에 참여 중입니다.

주된 실험내용은,

– Gene cloning – Mouse or human ES cell culture
– Adult stem cell culture – Epigenetics
– Blastocyst injection – ESC에서 differentiation
– Patch clamp(Electrophysiology) – Disease model study
– Recombinant protein synthesis – Drug screening

이며, 해당 기술 중 몇가지 항목이라도 능숙하게 실험할수 있는 학생을 우대 합니다.

⊙ 연구성과

인간 iPS를 제작하고, 이를 이용한 신경줄기세포분화기법 핵심기술을 보유

1. Kim et al., Direct Reprogramming of Human Neural Stem Cells by OCT4. Nature 2009;461(7264):649-653.
2. Kim et al., Generation of induced pluripotent stem cells from neural stem cells. Nature Protocols 2009;4(10):1464-1470.
3. Kim et al., Oct4-Induced Pluripotency in Adult Neural Stem Cells. Cell 2009;136:411-419.
4. Kim et al., Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008;454:646-650.

이외 iPS제작의 원천기술에 관한 국제특허 등록; Generation of induced pluripotent stem (iPS) cells(WO/2009/144008)

– 전형방법 : 서류전형, 면접전형
– 구비서류 : 이력서, 자기소개서, 논문/초록목록, 학위증명서, 성적증명서

위와 관련된 모든사항을 요구하는 것이 아니기에 특정분야에 관련 기술을 보유하거나
새로운 분야개척에 도전할줄 아는 패기와 열정을 갖춘 학생을 기다립니다.

연락처: jbkim@unist.ac.kr 으로
CV 및 자기소개서, 성적증명서, 영어성적증명서, 학위증명서, Publication list를 보내주시기 바랍니다.

Publication

Publications

Lee, H.; Lee, H.Y.; Lee, B.E.; Gerovska, D.; Park, S.Y.; Zaehres, H.; Araúzo-Bravo, M.J.; Kim, J.I.; Ha, Y.; Schöler, H.R.; Kim, J.B.; et al. Sequentially induced motor neurons from human fibroblasts facilitate locomotor recovery in a rodent spinal cord injury model. eLife 2020, 9

Park, S.Y.; Kang, J.Y.; Lee, T.; Nam, D.; Jeon, C.J.; Kim, J.B. SPON1 Can Reduce Amyloid Beta and Reverse Cognitive Impairment and Memory Dysfunction in Alzheimer’s Disease Mouse Model. Cells 2020, 9

Park, S.Y.; Lee, H.; Kwon, Y.W.; Park, M.R.; Kim, J.H.; Kim, J.B. Etv2- and Fli1-Induced Vascular Progenitor Cells Enhance Functional Recovery in Ischemic Vascular Disease Model. Arteriosclerosis, thrombosis, and vascular biology 2020, 10.1161/ATVBAHA.119.313684, ATVBAHA119313684

Park, M.R.; Wong, M.S.; Arauzo-Bravo, M.J.; Lee, H.; Nam, D.; Park, S.Y.; Seo, H.D.; Lee, S.M.; Zeilhofer, H.F.; Zaehres, H., et al. Oct4 and Hnf4alpha-induced hepatic stem cells ameliorate chronic liver injury in liver fibrosis model. PloS one 2019, 14, e0221085

Lee, H.; Nam, D.; Choi, J.K.; Arauzo-Bravo, M.J.; Kwon, S.Y.; Zaehres, H.; Lee, T.; Park, C.Y.; Kang, H.W.; Scholer, H.R., et al. Establishment of feeder-free culture system for human induced pluripotent stem cell on DAS nanocrystalline graphene. Scientific reports 2016, 6, 20708

Kim SM, Lim KT, Kwak TH, Lee SC, Im JH, Hali S, In Hwang S, Kim D, Hwang J, Kim KP, Chung HJ, Kim JB, Ko K, Chung HM, Lee HT, Schöler HR, Han DW
Induced neural stem cells from distinct genetic backgrounds exhibit different reprogramming status. Stem Cells Res. 2016 Feb 10; 16(2): 460 – 468

Andreas Hermann, Jeong Beom Kim, Sumitra Srimasorn, Holm Zaehres, Peter Reinhardt, Hans R. Schöler, and Alexander Storch
Factor-Reduced Human Induced Pluripotent Stem Cells Efficiently Differentiate into Neurons Independent of the Number of Reprogramming Factors. Stem Cells International. 2016 Feb; 2016(1): 1 – 6

Jeong Beom Kim, Hyunah Lee, Marcos J Araúzo-Bravo, Kyujin Hwang, Donggyu Nam, Myung Rae Park, Holm Zaehres, Kook In Park, Seok-Jin Lee
Oct4-induced oligodendrocyte progenitor cells enhance functional recovery in spinal cord injury model. EMBO journal. 2015 Oct; 34(20): 2483 – 2596

Se-Yang Kim, Jinsung Kwak, Jae Hwan Chu, Jeong Beom Kim, Sung Youb Kim, Kibog Park , and Soon-Yong Kwon
Controllable Synthesis of Graphene Encapsulated Low-Dimensional Nanocomposites. Advanced materials interfaces. 2015 Jun;2(11):1-7

Dorn I, Klich K, Arauzo-Bravo MJ, Radstaak M, Santourlidis S, Ghanjati F, Radke TF, Psathaki OE, Hargus G, Kramer J, Einhaus M, Kim JB, Kögler G, Wernet P, Schöler HR, Schlenke P, Zaehres H.
Erythroid differentiation of human induced pluripotent stem cells is independent of donor cell type of origin. Haematologica. 2015 Jan;100(1):32-41

Gunnar Hargus, Marc Ehrlich, Marcos J. Arau´ zo-Bravo, Kathrin Hemmer, Anna-Lena Hallmann, Peter Reinhardt, Kee-Pyo Kim, Kenjiro Adachi, Simeo Santourlidis, Foued Ghanjati, Mareike Fauser, Christiana Ossig, Alexander Storch, Jeong Beom Kim, Jens C. Schwamborn, Jared Sterneckert, Hans R. Scho¨ ler, Tanja Kuhlmann, and Holm Zaehres.
Origin-Dependent Neural Cell Identities in Differentiated Human iPSCs In Vitro and after Transplantation into the Mouse Brain.Cell reports. 2014 Sep;8(6):1-7

Yang K, Lee JS, Kim J, Lee YB, Shin H, Um SH, Kim JB, Park KI, Lee H, Cho SW.
Polydopamine-mediated surface modification of scaffold materials for human neural stem cell engineering. Biomaterials. 2012 Oct;33(29):6952-64.

Löhle M, Hermann A, Glass H, Kempe A, Schwarz SC, Kim JB, Poulet C, Ravens U, Schwarz J, Schöler HR, Storch A.
Differentiation efficiency of induced pluripotent stem cells depends on the number of reprogramming factors. Stem cells. 2012 2012 Mar;30(3):570-9. doi: 10.1002/stem.1016.

Minnerup J, Kim JB, Schmidt A, Diederich K, Bauer H, Schilling M, Strecker JK, Ringelstein EB, Sommer C, Schöler HR, Schabitz WR.
Effects of neural progenitor cells on sensorimotor recovery and endogenous repair mechanisms after photothrombotic stroke. Stroke. 2011 Jun; 42(6):1757-63.

Zhou H, Li W, Zhu S, Joo JY, Do JT, Xiong W, Kim JB, Zhang K, Schöler HR, Ding S.
Conversion of mouse epiblast stem cells to an earlier pluripotency state by small molecules. J Biol Chem. 2010 Sep 24; 285(39):29676-80.Epub 2010 Aug 12.

Zaehres H, Kim JB, Schöler HR.
Induced pluripotent stem cells. Methods Enzymol. 2010;476:309-25.

Zaehres H, Kögler G, Arauzo-Bravo MJ, Bleidissel M, Santourlidis S, Weinhold S, Greber B, Kim JB, Buchheiser A, Liedtke S, Eilken HM, Graffmann N, Zhao X, Meyer J, Reinhardt P, Burr B, Waclawczyk S, Ortmeier C, Uhrberg M, Schöler HR, Cantz T, Wernet P.
Induction of pluripotency in human cord blood unrestricted somatic stem cells. Exp Hematol. 2010 Sep; 38(9):809-18,818.e1-2. Epub 2010 Jun 10.

Kim, J. B., Greber, B., Arauzo-Bravo, M. J., Meyer, J., Park, K. I., Zaehres, H., Schöler HR.
Direct Reprogramming of Human Neural Stem Cells by Oct4. Nature 2009;461(7264):649-653.

Kim J. B., Zaehres, H., Arauzo-Bravo, M. J., Schöler HR.
Gerneration of induced pluripotent stem cells from neural stem cells. Nature Protocols 2009;4(10):1464-1470.

Ko, K., Tapia, N., Wu, G., Kim, J. B., Arauzo-Bravo, M. J., Sasse, P., Schöler HR.
Induction of Pluripotency in Adult Unipotent Germline Stem Cells. Cell Stem Cells 2009;5:87-96.

Kim J. B., Sebastiano, V., Wu, G., Arauzo-Bravo, M. J., Sasse, P., Gentile, L., Zaehres, H.,and Schöler HR.
Oct-4 Induced Pluripotency in Adult Neural Stem Cells. Cell 2009;136:411-419.

Kim, J. B., Zaehres, H., Wu, G., Schöler HR.
Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008;454:646-650.

Graumann J, Hubner NC, Kim J. B., Schöler H, Mann M.
Stable isotope labeling by amino acids in cell culture (SILAC)
and proteome quantitation of mouse embryonic stem cells to a depth of 5,111 proteins. Mol Cell Proteomics 2008;7(4):672-683.

 

Patents

03/25/2020. Composition for direct conversion from somatic cell to liver non-parenchymal cells and use thereof. Korea Patent. 10-2095483

02/12/2020. Hydrogel patches for regenerating or restoring injured tissues. Korea Patent. 10-2078788

02/12/2020. Hydrogel patches and pharmaceutical composition for treating traumatic spinal cord injury. Korea Patent. 10-2078789

02/12/2020. Hydrogel patches and pharmaceutical composition for treating spinal cord injury comprising hyaluronic acid. Korea Patent. 10-2078790

01/30/2020. Hydorgel patch. Australia Patent. 2018236629 (Patent granted decision made)

01/08/2019. Composition for inducing direct transdifferentiation of somatic cell into vascular progenitor cell, and use thereof. US Patent. 10174287

12/10/2019. Hydorgel patch. Korea Patent. 10-2056391

04/03/2019. Composition for inducing direct conversion of somatic cell into hepatic stem cell, hepatic cell, or cholangiocyte. Korea Patent. 10-1967435

10/26/2017. Composition for inducing direct conversion of somatic cell into Oligodendrocyte Progenitor Cells and use the same. Korea Patent. 10-731068

04/21/2017. Composition for inducing direct conversion of somatic cell into Oligodendrocyte Progenitor Cells and use the same. Korea Patent. 10-792757

05/15/2017.Feeder-free culture system for human pluripotent stem cell. Korea Patent. 10-737796

01/26/2017. Composition for inducing direct conversion of somatic cell into Vascular Progenitor Cells and use the same. Korea Patent. 10-1702629

12/3/2009. International Patent: Generation of induced Pluripotent Stem (iPS) cells, WO 2009/144008.

9/4/2013, China Patent: Generation of induced Pluripotent Stem (iPS) cells, CN 102066556 B.

Research

Welcome to the Molecular Biomedicine Laboratory (MBL)
By 박수용 2020-06-11

The paradigm of regenerative medicine was thoroughly changed when induced pluripotent stem cells (iPS) were first derived by Shinya Yamanaka. Importantly, iPS can be used as a source for patient-specific cell therapies. In addition, the ethical concerns and the limitations associated with embryonic stem cell (ESC), namely immune rejection, could also be overcome.
Direct conversion is another innovative technique. Because it doesn’t need iPS intermediate state to make patients specific stem cells, it can rule out the possibility of tumorigenicity.

Our research is based on an understanding of the mechanism of iPS reprogramming, direct conversion, and the generation of patient-specific stem cells for future cell therapy. The aim is to develop innovative cell therapeutic methods for clinical applications and possible solutions for a degenerative and currently incurable disease. In addition, iPS cells and direct conversion can also be used for innovative techniques of drug screening and toxicity tests. Therefore, the therapeutic potential of iPS cells and directly converted cells are very promising.
figure 2
Moreover, we are collaborating with the Max Planck Institute for Molecular Biomedicine (MPI-MBM) located in Muenster, Germany. This collaboration will create synergic effects that will be mutually beneficial. Continuously seeking new areas of collaboration, we will reach out to become a world-class stem cell research group.

Hans Schoeler Stem Cell Research Center (HSSCRC) — Hans Schoeler Stem Cell Research Center (HSSCRC)

Hans Schöler Stem Cell Research Center (HSSCRC) is a globally expanding stem cell research facility focusing on regenerative medicine. It consists of 4 departments with 30 researchers. Within 3 years, the number of researchers will reach 100, including joint researchers. HSSCRC will be sponsored by UNIST with 80 billion WON during the next 6 years and the construction of the facility building is scheduled to be completed in August of 2012.
hans
As the first iPS cell research center established in Korea, Hans Schöler Stem Cell Research Center (HSSCRC) uses the methods of reprogramming and direct conversion of the somatic cells extracted from the patient and produces “patient-specific stem cell” for therapeutic purposes by a multi-disciplinary approach. Our primary goal is to develop novel therapies to regenerate damaged tissues and overcome debilitating chronic disease. Patient-specific cell therapy, which is produced by reprogramming and direct conversion, can be useful for researches on the mechanism of disease occurrence and patient-specific drug screening tests and will be provided the limitless potential in the field of regenerative medicine.

Germany-based Max Planck Gesellschaft (MPG) partner group
By 박수용 2020-06-11

partner group
UNIST-Molecular Biomedince Laboratory(MBL) nominated a partner group (42nd) with Max Planck Institute in January of 2012 to enhance cooperation with the international stem cell institute for joint research.
partner

Resources

Jeong Beom Kim

+82-52-217- 5201